nmCRPC

PSA Doubling Time – A Significant Prognostic Marker 

PSA Doubling Time – A Significant Prognostic Marker 

Shorter prostate-specific antigen doubling time was significantly associated with shorter metastasis-free survival and overall survival.

The development of metastasis was associated with a 3-fold higher risk of death.

The onset of non-metastatic castrate-resistant prostate cancer and metastatic castrate-resistant prostate cancer was associated with substantial cost increases.

ARAMIS Trial Finds That the Investigational Treatment Darolutamide Extends Metastasis-free Survival of Men with M0 Castrate Resistant Prostate Cancer

It has been announced that the Phase III ARAMIS Trial (Androgen Receptor inhibiting Agent for Metastatic-free Survival) evaluating an investigational treatment known as darolutamide in men with Non-metastatic Castration-resistant Prostate Cancer (nM0) has successfully met its primary endpoint of extending the metastasis-free survival (MFS) of men compared to placebo.